GENX — Genix Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- CA$1.22m
- CA$2.47m
Annual income statement for Genix Pharmaceuticals, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.012 | 0.004 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 0.003 | 0.001 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.66 | 1.03 | 4.35 | -0.041 | 0.163 |
| Operating Profit | -1.66 | -1.03 | -4.34 | 0.045 | -0.163 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.65 | -1.07 | -4.4 | -0.073 | -0.335 |
| Net Income After Taxes | -1.65 | -1.07 | -4.4 | -0.073 | -0.335 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.65 | -1.07 | -4.4 | -0.073 | -0.335 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.65 | -1.07 | -4.4 | -0.073 | -0.335 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.028 | -0.018 | -0.016 | -0.006 | -0.006 |